

INFORMATION DISCLOSED
CITATION

PTO-1449

OCT 16 2000

ATTY. DOCKET NO.
A-68126-1/RFT/RMSSERIAL NO.
09/502,984

RECEIVED

APPLICANT
PEIZHI et al.

OCT 19 2000

FILING DATE
February 11, 2000GROUP
1631

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS								
EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<i>JZ</i>	1	5,292,654.0	03/1994	Yoshimura et al.				
FOREIGN PATENT DOCUMENTS							Translation	
EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Yes	No
<i>JZ</i>	2	94/29458	12/1994	PCT				
<i>JZ</i>	3	98/47089	10/1998	PCT				
<i>JZ</i>	4	0 742 438	11/1996	EP	<i>ABSTRACT ON</i>			
<i>JZ</i>	5	0 603 8787	02/1994	EP (patent abstracts of Japan)				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	6	Dahiyat et al., "Protein design automation," <i>Protein Science</i> , 5:895-903 (1996).						
	7	Jolliffe et al., "Erythropoietin Receptor: Application in Drug Development," <i>Nephrol. Cial. Transplant.</i> , 10(suppl. 2): 28-34 (1995).						
	8	Quelle et al., "Mutations in the WSAWSE and Cytosolic Domains of the Erythropoietin Receptor Affect Signal Transduction and Ligand Binding and Internalization," <i>Molecular and Cellular Biology</i> , 12(10): 4553-4561 (1992).						
	9	Barbone et al., "Mutagenesis Studies of the Human Erythropoietin Receptor," <i>The Journal of Biological Chemistry</i> , 272(8): 4985-4992 (1997).						
	10	Johnson et al., "Refolding, Purification, and Characterization of Human Erythropoietin Binding Protein Produced in <i>Escherichia coli</i> ," <i>Protein Expression and Purification</i> , 7:104-113 (1996).						
	11	Livnah et al., "An Antagoisnt Peptide-EPO Receptor Complex Suggests that Receptor Dimerization is not Sufficient for Actviation," <i>Nature Structural Biology</i> , 5(11): 993-1003 (1998).						
	12	McConnell et al., Isolation of Erythropoietin Recetpor Agonist Peptides Using Evolved Phage Libraries," <i>Biol. Chem.</i> , 379:1279-1286 (1998).						
	13	Wrighton et al., "Small Peptides as potent Mimetics of the Protein Hormone Erythropoietin," <i>Science</i> , 273:458-463 (1996).						
	14	Edgington, S. "Superfamily Structure And Biotech Drug Development," <i>Biotechnology</i> , 10:1529-1534 (1992).						
	15	Middleton et al., "Critical Erythropoietin (EPO) Binding Determinanats on the EPO Receptor also Interact," <i>Blood</i> , 88(10): 661A, abstract (1996).						
	16	Borman, "Proteins to Order," <i>Chemical and Engineering Newsletter (C&EN)</i> October 6, 1997, 9-10 (1997).						
	17	Lazar et al., "De novo design of the hydrophobic core of ubiquitin," <i>Protein Science</i> 6:1167-1178 (1997).						
	18	Desjarlais et al., "New strategies in protein design," <i>Current Opinion in Biotechnology</i> ^:460-466 (1995).						
EXAMINER	<i>JZ</i>	DATE CONSIDERED						<i>1/24/01</i>

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 8085 1449A.FRM (8/95)